XBIT
Xbiotech·NASDAQ
--
--(--)
--
--(--)
7.03 / 10
Outperform
Capital flows are favorable, registering 7.03/10 with positive large-cap inflows (0.51) despite negative overall trends. No analyst coverage is available. The robust fund flow partially offsets weak technicals, but the absence of analyst insights limits forward-looking validation. Investors should monitor liquidity signals and await clearer technical or fundamental catalysts.
Fund Flow Rating
What is the market sentiment for XBIT?
- XBIT holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.03/10 (Outperform).
